Results 31 to 40 of about 1,936 (153)

Ceftolozane-tazobactam in nosocomial pneumonia

open access: yesRevista Española de Quimioterapia, 2022
Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the ...
Candel, Francisco Javier   +3 more
openaire   +2 more sources

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

open access: yesInternational Journal of Infectious Diseases, 2021
: Objectives: To report on the activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa isolates collected from hospitalized patients with pneumonia in US intensive care units (ICUs) between 2015 and 2018. Activity against all P.
Michael A. Pfaller   +7 more
doaj   +1 more source

Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia [PDF]

open access: yes, 2020
Objectives: Ceftolozane/tazobactam is approved for hospital-acquired/ventilator-associated bacterial pneumonia at double the dose (i.e. 2 g/1 g) recommended for other indications.
Nicolau, David P   +9 more
core   +1 more source

Comparison of the

open access: yesJournal of Global Antimicrobial Resistance
Objectives: To provide a descriptive analysis of the in vitro antimicrobial susceptibility testing results for all 39,661 Pseudomonas aeruginosa isolates collected by the ATLAS global surveillance programme data from 2020 to 2024 with a focus on ...
Mark A. Estabrook   +3 more
doaj   +1 more source

Pharmacokinetics of ceftolozane-tazobactam during prolonged intermittent renal replacement therapy

open access: yes, 2018
Background: Prolonged intermittent renal replacement therapy (PIRRT) eliminates many drugs, and without dosing data, for new antibiotics like ceftolozane/tazobactam, suboptimal concentrations and treatment failure are likely.
Regli, Adrian   +8 more
core   +1 more source

The Comparative Effectiveness of Ceftolozane/Tazobactam versus Aminoglycoside- or Polymyxin-Based Regimens in Multi-Drug-Resistant Pseudomonas aeruginosa Infections

open access: yesAntibiotics, 2022
Pseudomonas aeruginosa infections are challenging to treat due to multi-drug resistance (MDR) and the complexity of the patients affected by these serious infections.
Aisling R. Caffrey   +7 more
doaj   +1 more source

Determination of Total and Free Ceftolozane and Tazobactam in Human Plasma and Interstitial Fluid by HPLC-UV

open access: yes, 2018
Ceftolozane/tazobactam is a new cephalosporin/beta-lactamase inhibitor combination. An HPLC-UV method is described for the determination of total and free ceftolozane and tazobactam in human plasma and in microdialysate of subcutaneous tissue ...
Kees, Frieder   +7 more
core   +1 more source

Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation [PDF]

open access: yes, 2016
Ceftolozane-tazobactam has potent activity against Pseudomonas aeruginosa , a pathogen associated with cystic fibrosis (CF) acute pulmonary exacerbations (APE).
Muhlebach, Marianne   +5 more
core   +1 more source

Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

open access: yesBiofilm
Objectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations
María Fernández-Billón   +9 more
doaj   +1 more source

Osteomyelitis: Epidemiology, Classification, Pathophysiology, Clinical Features, Diagnosis, and Management

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The immunosuppressive in OM Staphylococcus aureus employs multiple physical barriers to evade host immunity during skeletal infection, including biofilm formation on implant surfaces and necrotic bone tissues, invasion into the osteocyte lacuno‐canalicular network (OLCN), intracellular persistence within osteoblasts, osteoclasts, and osteocytes, and ...
Qingqiang Lei   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy